|
1
|
Ferlay J, Colombet M, Soerjomataram I,
Parkin DM, Piñeros M, Znaor A and Bray F: Cancer statistics for the
year 2020: An overview. Int J Cancer. April 5–2021.(Epub ahead of
print). View Article : Google Scholar
|
|
2
|
Rogers TJ: Kappa opioid receptor
expression and function in cells of the immune system. Handb Exp
Pharmacol. 271:419–433. 2022. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Trescot AM: Review of the role of opioids
in cancer pain. J Natl Compr Cancer Netw. 8:1087–1094. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Lohse I and Brothers SP: Pathogenesis and
treatment of pancreatic cancer related pain. Anticancer Res.
40:1789–1796. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mercadante S and Vitrano V: Pain in
patients with lung cancer: Pathophysiology and treatment. Lung
Cancer. 68:10–15. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Szczepaniak A, Fichna J and Zielińska M:
Opioids in cancer development, progression and metastasis: Focus on
colorectal cancer. Curr Treat Options Oncol. 21:62020. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Satija A, Ahmed SM, Gupta R, Ahmed A, Rana
SPS, Singh SP, Mishra S and Bhatnagar S: Breast cancer pain
management-a review of current & novel therapies. Indian J Med
Res. 139:216–225. 2014.PubMed/NCBI
|
|
8
|
Ing JW: Head and neck cancer pain.
Otolaryngol Clin North Am. 50:793–806. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lu H, Zhang H, Weng ML, Zhang J, Jiang N,
Cata JP, Ma D, Chen WK and Miao CH: Morphine promotes tumorigenesis
and cetuximab resistance via EGFR signaling activation in human
colorectal cancer. J Cell Physiol. 236:4445–4454. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ma Y, Ren Z, Ma S, Yan W, He M, Wang D and
Ding P: Morphine enhances renal cell carcinoma aggressiveness
through promotes survivin level. Ren Fail. 39:258–264. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ustun F, Durmus-Altun G, Altaner S,
Tuncbilek N, Uzal C and Berkarda S: Evaluation of morphine effect
on tumour angiogenesis in mouse breast tumour model, EATC. Med
Oncol. 28:1264–1272. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Guerrero Orriach JL, Raigon Ponferrada A,
Malo Manso A, Herrera Imbroda B, Escalona Belmonte JJ, Ramirez
Aliaga M, Ramirez Fernandez A, Crespo JD, Soriano Perez AM,
Fontaneda Heredia A, et al: Anesthesia in combination with propofol
increases disease-free survival in bladder cancer patients who
undergo radical tumor cystectomy as compared to inhalational
anesthetics and opiate-based analgesia. Oncology. 98:161–167. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Hasegawa T, Oguri T, Osawa T, Sawa T,
Osaga S, Okuyama T, Uchida M, Maeno K, Fukuda S, Nishie H, et al:
Opioid dose and survival of patients with incurable nonsmall cell
lung cancer: A prospective cohort study. J Palliat Med.
21:1436–1441. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Gong S, Ying L, Fan Y and Sun Z: Fentanyl
inhibits lung cancer viability and invasion via upregulation of
miR-331-3p and repression of HDAC5. Onco Targets Ther.
13:13131–13141. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Li C, Qin Y, Zhong Y, Qin Y, Wei Y, Li L
and Xie Y: Fentanyl inhibits the progression of gastric cancer
through the suppression of MMP-9 via the PI3K/Akt signaling
pathway. Ann Transl Med. 8:1182020. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Zhang XL, Chen ML and Zhou SL: Fentanyl
inhibits proliferation and invasion of colorectal cancer via
β-catenin. Int J Clin Exp Pathol. 8:227–235. 2015.PubMed/NCBI
|
|
17
|
Sasamura T, Nakamura S, Iida Y, Fujii H,
Murata J, Saiki I, Nojima H and Kuraishi Y: Morphine analgesia
suppresses tumor growth and metastasis in a mouse model of cancer
pain produced by orthotopic tumor inoculation. Eur J Pharmacol.
441:185–191. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Fichna J and Janecka A: Opioid peptides in
cancer. Cancer Metastasis Rev. 23:351–366. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Chatikhine VA, Chevrier A, Chauzy C, Duval
C, d'Anjou J, Girard N and Delpech B: Expression of opioid peptides
in cells and stroma of human breast cancer and adenofibromas.
Cancer Lett. 77:51–56. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Zagon IS, Hytrek SD and McLaughlin PJ:
Opioid growth factor tonically inhibits human colon cancer cell
proliferation in tissue culture. Am J Physiol. 271:R511–R518.
1996.PubMed/NCBI
|
|
21
|
Hatzoglou A, Gravanis A, Margioris AN,
Zoumakis E and Castanas E: Identification and characterization of
opioid-binding sites present in the Ishikawa human endometrial
adenocarcinoma cell line. J Clin Endocrinol Metab. 80:418–423.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Roth KA and Barchas JD: Small cell
carcinoma cell lines contain opioid peptides and receptors. Cancer.
57:769–773. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Singleton PA, Mirzapoiazova T, Hasina R,
Salgia R and Moss J: Increased µ-opioid receptor expression in
metastatic lung cancer. Br J Anaesth. 113 (Suppl 1):i103–i108.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lennon FE, Mirzapoiazova T, Mambetsariev
B, Salgia R, Moss J and Singleton PA: Overexpression of the
µ-opioid receptor in human non-small cell lung cancer promotes Akt
and mTOR activation, tumor growth, and metastasis. Anesthesiology.
116:857–867. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wolff RF, Aune D, Truyers C, Hernandez AV,
Misso K, Riemsma R and Kleijnen J: Systematic review of efficacy
and safety of buprenorphine versus fentanyl or morphine in patients
with chronic moderate to severe pain. Curr Med Res Opin.
28:833–845. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Cieślińska A, Sienkiewicz-Szłapka E,
Kostyra E, Fiedorowicz E, Snarska J, Wroński K, Tenderenda M,
Jarmołowska B and Matysiewicz M: µ-Opioid receptor gene (OPRM1)
polymorphism in patients with breast cancer. Tumour Biol.
36:4655–4660. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Singleton PA, Moss J, Karp DD, Atkins JT
and Janku F: The mu opioid receptor: A new target for cancer
therapy? Cancer. 121:2681–2688. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Steele GL, Dudek AZ, Gilmore GE, Richter
SA, Olson DA, Eklund JP and Zylla DM: Impact of pain, opioids, and
the mu-opioid receptor on progression and survival in patients with
newly diagnosed stage IV pancreatic cancer. Am J Clin Oncol.
43:591–597. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Kim J, Ham S, Hong H, Moon C and Im HI:
Brain reward circuits in morphine addiction. Mol Cells. 39:645–653.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Benyamin R, Trescot AM, Datta S,
Buenaventura R, Adlaka R, Sehgal N, Glaser SE and Vallejo R: Opioid
complications and side effects. Pain Physician. 11 (Suppl
2):S105–S120. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bodnar RJ: Endogenous opioid modulation of
food intake and body weight: Implications for opioid influences
upon motivation and addiction. Peptides. 116:42–62. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Bagley EE and Ingram SL: Endogenous opioid
peptides in the descending pain modulatory circuit.
Neuropharmacology. 173:1081312020. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Barron BA: Opioid peptides and the heart.
Cardiovasc Res. 43:13–16. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Gein SV and Baeva TA: Endogenous opioid
peptides in regulation of innate immunity cell functions.
Biochemistry (Mosc). 76:309–319. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Mercadante S and Romualdi P: The
therapeutic potential of novel kappa opioid receptor-based
treatments. Curr Med Chem. 27:2012–2020. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Waldhoer M, Bartlett SE and Whistler JL:
Opioid receptors. Annu Rev Biochem. 73:953–990. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Minami M, Toya T, Katao Y, Maekawa K,
Nakamura S, Onogi T, Kaneko S and Satoh M: Cloning and expression
of a cDNA for the rat kappa-opioid receptor. FEBS Lett.
329:291–295. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Schoffelmeer AN, Hogenboom F and Mulder
AH: Kappa1- and kappa2-opioid receptors mediating presynaptic
inhibition of dopamine and acetylcholine release in rat
neostriatum. Br J Pharmacol. 122:520–524. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Brooks AI, Standifer KM, Rossi GC, Mathis
JP and Pasternak GW: Characterizing kappa3 opioid receptors with a
selective monoclonal antibody. Synapse. 22:247–252. 1996.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Cahill CM, Taylor AM, Cook C, Ong E, Morón
JA and Evans CJ: Does the kappa opioid receptor system contribute
to pain aversion? Front Pharmacol. 5:2532014. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Crowley NA and Kash TL: Kappa opioid
receptor signaling in the brain: Circuitry and implications for
treatment. Prog Neuropsychopharmacol Biol Psychiatry. 62:51–60.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Ruan X, Mancuso KF and Kaye AD: Revisiting
oxycodone analgesia: A review and hypothesis. Anesthesiol Clin.
35:e163–e174. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Schmidt-Hansen M, Bennett MI, Arnold S,
Bromham N and Hilgart JS: Oxycodone for cancer-related pain.
Cochrane Database Syst Rev. 8:Cd0038702017.PubMed/NCBI
|
|
44
|
Jin WQ, Tai KK, Chan TK and Wong TM:
Further characterization of [3H]U69593 binding sites in the rat
heart. J Mol Cell Cardiol. 27:1507–1511. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Simonin F, Gavériaux-Ruff C, Befort K,
Matthes H, Lannes B, Micheletti G, Mattéi MG, Charron G, Bloch B
and Kieffer B: kappa-Opioid receptor in humans: cDNA and genomic
cloning, chromosomal assignment, functional expression,
pharmacology, and expression pattern in the central nervous system.
Proc Natl Acad Sci USA. 92:7006–7010. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Gavériaux-Ruff C, Peluso J, Befort K,
Simonin F, Zilliox C and Kieffer BL: Detection of opioid receptor
mRNA by RT-PCR reveals alternative splicing for the delta- and
kappa-opioid receptors. Brain Res Mol Brain Res. 48:298–304. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Wang YJ, Rasakham K, Huang P, Chudnovskaya
D, Cowan A and Liu-Chen LY: Sex difference in κ-opioid receptor
(KOPR)-mediated behaviors, brain region KOPR level and
KOPR-mediated guanosine 5′-O-(3-[35S]thiotriphosphate) binding in
the guinea pig. J Pharmacol Exp Ther. 339:438–450. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Machelska H and Celik M: Opioid receptors
in immune and glial cells-implications for pain control. Front
Immunol. 11:3002020. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Spasov AA, Grechko O and Shtareva DM:
Kappa-opioid receptor: Molecular structure and function. Eksp klin
Farmakol. 77:27–35. 2014.(In Russian).
|
|
50
|
Carroll FI and Carlezon WA Jr: Development
of κ opioid receptor antagonists. J Med Chem. 56:2178–2195. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Yamamizu K, Hamada Y and Narita M: κ
Opioid receptor ligands regulate angiogenesis in development and in
tumours. Br J Pharmacol. 172:268–276. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Shi Y, Luo J, Tian J, Zou Q and Wang X:
The kappa opioid receptor may be a potential tumor suppressor by
regulating angiogenesis in breast cancer. Med Hypotheses.
150:1105682021. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
Wigmore T and Farquhar-Smith P: Opioids
and cancer: Friend or foe? Curr Opin Support Palliat Care.
10:109–118. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Strang P: Cancer pain-a provoker of
emotional, social and existential distress. Acta Oncol. 37:641–644.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Reiche EM, Nunes SO and Morimoto HK:
Stress, depression, the immune system, and cancer. Lancet Oncol.
5:617–625. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Edwards KA, Havelin JJ, McIntosh MI,
Ciccone HA, Pangilinan K, Imbert I, Largent-Milnes TM, King T,
Vanderah TW and Streicher JM: A kappa opioid receptor agonist
blocks bone cancer pain without altering bone loss, tumor size, or
cancer cell proliferation in a mouse model of cancer-induced bone
pain. J Pain. 19:612–625. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Zhang YF, Xu QX, Liao LD, Xu XE, Wu JY,
Shen J, Wu ZY, Shen JH, Li EM and Xu LY: κ-Opioid receptor in the
nucleus is a novel prognostic factor of esophageal squamous cell
carcinoma. Hum Pathol. 44:1756–1765. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Diao CT, Li L, Lau SY, Wong TM and Wong
NS: kappa-Opioid receptor potentiates apoptosis via a phospholipase
C pathway in the CNE2 human epithelial tumor cell line. Biochim
Biophys Acta. 1499:49–62. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
59
|
Li H, Ma Z and Lei Y: The expression of
kappa-opioid receptor promotes the migration of breast cancer cells
in vitro. BMC Anesthesiol. 21:2102021. View Article : Google Scholar : PubMed/NCBI
|
|
60
|
Chen D, Chen Y, Yan Y, Pan J, Xing W, Li Q
and Zeng W: Down-regulation of the tumour suppressor κ-opioid
receptor predicts poor prognosis in hepatocellular carcinoma
patients. BMC Cancer. 17:5532017. View Article : Google Scholar : PubMed/NCBI
|
|
61
|
Tripolt S, Neubauer HA, Knab VM, Elmer DP,
Aberger F, Moriggl R and Fux DA: Opioids drive breast cancer
metastasis through the δ-opioid receptor and oncogenic STAT3.
Neoplasia. 23:270–279. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
62
|
Brejchova J, Holan V and Svoboda P:
Expression of opioid receptors in cells of the immune system. Int J
Mol Sci. 22:3152020. View Article : Google Scholar : PubMed/NCBI
|
|
63
|
Pert CB and Snyder SH: Opiate receptor:
Demonstration in nervous tissue. Science. 179:1011–1014. 1973.
View Article : Google Scholar : PubMed/NCBI
|
|
64
|
Kiguchi N, Ding H, Kishioka S and Ko MC:
Nociceptin/orphanin FQ peptide receptor-related ligands as novel
analgesics. Curr Top Med Chem. 20:2878–2888. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
65
|
Dhaliwal A and Gupta M: Physiology, opioid
receptor. StatPearls (Internet). StatPearls Publishing; Treasure
Island, FL: 2021
|
|
66
|
Valentino RJ and Volkow ND: Untangling the
complexity of opioid receptor function. Neuropsychopharmacology.
43:2514–2520. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
67
|
Chavkin C, James IF and Goldstein A:
Dynorphin is a specific endogenous ligand of the kappa opioid
receptor. Science. 215:413–415. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
68
|
Bruchas MR, Land BB and Chavkin C: The
dynorphin/kappa opioid system as a modulator of stress-induced and
pro-addictive behaviors. Brain Res. 1314:44–55. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
69
|
Terenius L: From opiate pharmacology to
opioid peptide physiology. Ups J Med Sci. 105:1–15. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
70
|
Goldstein A and Naidu A: Multiple opioid
receptors: Ligand selectivity profiles and binding site signatures.
Mol Pharmacol. 36:265–272. 1989.PubMed/NCBI
|
|
71
|
Giros B, Pohl M, Rochelle JM and Seldin
MF: Chromosomal localization of opioid peptide and receptor genes
in the mouse. Life Sci. 56:PL369–PL375. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
72
|
Wei LN and Loh HH: Transcriptional and
epigenetic regulation of opioid receptor genes: Present and future.
Annu Rev Pharmacol Toxicol. 51:75–97. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
73
|
Xie GX, Meng F, Mansour A, Thompson RC,
Hoversten MT, Goldstein A, Watson SJ and Akil H: Primary structure
and functional expression of a guinea pig kappa opioid (dynorphin)
receptor. Proc Natl Acad Sci USA. 91:3779–3783. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
74
|
Wu H, Wacker D, Mileni M, Katritch V, Han
GW, Vardy E, Liu W, Thompson AA, Huang XP, Carroll FI, et al:
Structure of the human κ-opioid receptor in complex with JDTic.
Nature. 485:327–332. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
75
|
Akil H and Watson SJ: Cloning of kappa
opioid receptors: Functional significance and future directions.
Prog Brain Res. 100:81–86. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
76
|
Law PY, Loh HH and Wei LN: Insights into
the receptor transcription and signaling: Implications in opioid
tolerance and dependence. Neuropharmacology. 47 (Suppl
1):S300–S311. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
77
|
Al-Hasani R and Bruchas MR: Molecular
mechanisms of opioid receptor-dependent signaling and behavior.
Anesthesiology. 115:1363–1381. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
78
|
Bruchas MR, Xu M and Chavkin C: Repeated
swim stress induces kappa opioid-mediated activation of
extracellular signal-regulated kinase 1/2. Neuroreport.
19:1417–1422. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
79
|
Kam AY, Chan AS and Wong YH: Kappa-opioid
receptor signals through Src and focal adhesion kinase to stimulate
c-Jun N-terminal kinases in transfected COS-7 cells and human
monocytic THP-1 cells. J Pharmacol Exp Ther. 310:301–310. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
80
|
Finley MJ, Steele A, Cornwell WD and
Rogers TJ: Transcriptional regulation of the major HIV-1
coreceptor, CXCR4, by the kappa opioid receptor. J Leukoc Biol.
90:111–121. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
81
|
Georgoussi Z, Georganta EM and Milligan G:
The other side of opioid receptor signalling: Regulation by
protein-protein interaction. Curr Drug Targets. 13:80–102. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
82
|
Fink RM and Gallagher E: Cancer pain
assessment and measurement. Semin Oncol Nurs. 35:229–234. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
83
|
Wiffen PJ, Cooper TE, Anderson AK, Gray
AL, Grégoire MC, Ljungman G and Zernikow B: Opioids for
cancer-related pain in children and adolescents. Cochrane Database
Syst Rev. 7:Cd0125642017.PubMed/NCBI
|
|
84
|
Wiffen PJ, Wee B, Derry S, Bell RF and
Moore RA: Opioids for cancer pain-an overview of cochrane reviews.
Cochrane Database Syst Rev. 7:Cd0125922017.PubMed/NCBI
|
|
85
|
Paton KF, Atigari DV, Kaska S, Prisinzano
T and Kivell BM: Strategies for developing κ opioid receptor
agonists for the treatment of pain with fewer side effects. J
Pharmacol Exp Ther. 375:332–348. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
86
|
Escobar ADP, Casanova JP, Andrés ME and
Fuentealba JA: Crosstalk between kappa opioid and dopamine systems
in compulsive behaviors. Front Pharmacol. 11:572020. View Article : Google Scholar : PubMed/NCBI
|
|
87
|
McLaughlin JP, Li S, Valdez J, Chavkin TA
and Chavkin C: Social defeat stress-induced behavioral responses
are mediated by the endogenous kappa opioid system.
Neuropsychopharmacology. 31:1241–1248. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
88
|
Knoll AT and Carlezon WA Jr: Dynorphin,
stress, and depression. Brain Res. 1314:56–73. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
89
|
Carlezon WA Jr and Krystal AD:
Kappa-Opioid antagonists for psychiatric disorders: From bench to
clinical trials. Depress Anxiety. 33:895–906. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
90
|
Falcon E, Maier K, Robinson SA, Hill-Smith
TE and Lucki I: Effects of buprenorphine on behavioral tests for
antidepressant and anxiolytic drugs in mice. Psychopharmacology
(Berl). 232:907–915. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
91
|
Ahmadi J, Jahromi MS and Ehsaei Z: The
effectiveness of different singly administered high doses of
buprenorphine in reducing suicidal ideation in acutely depressed
people with co-morbid opiate dependence: A randomized,
double-blind, clinical trial. Trials. 19:4622018. View Article : Google Scholar : PubMed/NCBI
|
|
92
|
Serafini G, Adavastro G, Canepa G, De
Berardis D, Valchera A, Pompili M, Nasrallah H and Amore M: The
efficacy of buprenorphine in major depression, treatment-resistant
depression and suicidal behavior: A systematic review. Int J Mol
Sci. 19:24102018. View Article : Google Scholar : PubMed/NCBI
|
|
93
|
Wang Q, Long Y, Hang A, Zan GY, Shu XH,
Wang YJ and Liu JG: The anxiolytic- and antidepressant-like effects
of ATPM-ET, a novel κ agonist and µ partial agonist, in mice.
Psychopharmacology (Berl). 233:2411–2418. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
94
|
Kovalska M, Kovalska L, Tothova B, Mahmood
S, Adamkov M and Lehotsky J: Combination of hyperhomocysteinemia
and ischemic tolerance in experimental model of global ischemia in
rats. J Physiol Pharmacol. 66:887–897. 2015.PubMed/NCBI
|
|
95
|
Dennis TS, Beck KD, Cominski TP, Bobzean
SAM, Kuzhikandathil EV, Servatius RJ and Perrotti LI: Exposure to
morphine-associated cues increases mu opioid receptor mRNA
expression in the nucleus accumbens of Wistar Kyoto rats. Behav
Brain Res. 313:208–213. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
96
|
Menyhárt Á, Makra P, Szepes BE, Tóth OM,
Hertelendy P, Bari F and Farkas E: High incidence of adverse
cerebral blood flow responses to spreading depolarization in the
aged ischemic rat brain. Neurobiol Aging. 36:3269–3277. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
97
|
Chen C, Xi C, Liang X, Ma J, Su D, Abel T
and Liu R: The role of κ opioid receptor in brain ischemia. Crit
Care Med. 44:e1219–e1225. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
98
|
Sobanski P, Krajnik M, Shaqura M,
Bloch-Boguslawska E, Schäfer M and Mousa SA: The presence of mu-,
delta-, and kappa-opioid receptors in human heart tissue. Heart
Vessels. 29:855–863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
99
|
Jaiswal A, Kumar S, Seth S, Dinda AK and
Maulik SK: Effect of U50,488H, a κ-opioid receptor agonist on
myocardial α-and β-myosin heavy chain expression and oxidative
stress associated with isoproterenol-induced cardiac hypertrophy in
rat. Mol Cell Biochem. 345:231–240. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
100
|
Komaba H, Moriwaki K, Goto S, Yamada S,
Taniguchi M, Kakuta T, Kamae I and Fukagawa M: Cost-effectiveness
of cinacalcet hydrochloride for hemodialysis patients with severe
secondary hyperparathyroidism in Japan. Am J Kidney Dis.
60:262–271. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
101
|
Wang H, Wang JL, Ren HW, He WF and Sun M:
Butorphanol protects on myocardial ischemia/reperfusion injury in
rats through MAPK signaling pathway. Eur Rev Med Pharmacol Sci.
23:10541–10548. 2019.PubMed/NCBI
|
|
102
|
Brust TF, Morgenweck J, Kim SA, Rose JH,
Locke JL, Schmid CL, Zhou L, Stahl EL, Cameron MD, Scarry SM, et
al: Biased agonists of the kappa opioid receptor suppress pain and
itch without causing sedation or dysphoria. Sci Signal.
9:ra1172016. View Article : Google Scholar : PubMed/NCBI
|
|
103
|
Feng Y, He X, Yang Y, Chao D, Lazarus LH
and Xia Y: Current research on opioid receptor function. Curr Drug
Targets. 13:230–246. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
104
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
105
|
Llovet JM, Zucman-Rossi J, Pikarsky E,
Sangro B, Schwartz M, Sherman M and Gores G: Hepatocellular
carcinoma. Nat Rev Dis Primers. 2:160182016. View Article : Google Scholar : PubMed/NCBI
|
|
106
|
DeSantis CE, Lin CC, Mariotto AB, Siegel
RL, Stein KD, Kramer JL, Alteri R, Robbins AS and Jemal A: Cancer
treatment and survivorship statistics, 2014. CA Cancer J Clin.
64:252–271. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
107
|
Maneckjee R and Minna JD: Opioid and
nicotine receptors affect growth regulation of human lung cancer
cell lines. Proc Natl Acad Sci USA. 87:3294–3298. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
108
|
Kuzumaki N, Suzuki A, Narita M, Hosoya T,
Nagasawa A, Imai S, Yamamizu K, Morita H, Nagase H, Okada Y, et al:
Effect of κ-opioid receptor agonist on the growth of non-small cell
lung cancer (NSCLC) cells. Br J Cancer. 106:1148–1152. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
109
|
Sim EH, Yang IA, Wood-Baker R, Bowman RV
and Fong KM: Gefitinib for advanced non-small cell lung cancer.
Cochrane Database Syst Rev. 1:CD0068472018.PubMed/NCBI
|
|
110
|
Bareschino MA, Schettino C, Troiani T,
Martinelli E, Morgillo F and Ciardiello F: Erlotinib in cancer
treatment. Ann Oncol. 18 (Suppl 6):vi35–vi41. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
111
|
Rho JK, Choi YJ, Ryoo BY, Na III, Yang SH,
Kim CH and Lee JC: p53 enhances gefitinib-induced growth inhibition
and apoptosis by regulation of Fas in non-small cell lung cancer.
Cancer Res. 67:1163–1169. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
112
|
An WF, Germain AR, Bishop JA, Nag PP,
Metkar S, Ketterman J, Walk M, Weiwer M, Liu X, Patnaik D, et al:
Discovery of potent and highly selective inhibitors of GSK3b. Probe
Reports from the NIH Molecular Libraries Program. National Center
for Biotechnology Information (US); Bethesda (MD): 2010, PubMed/NCBI
|
|
113
|
Tian D, Zhu M, Chen WS, Li JS, Wu RL and
Wang X: Role of glycogen synthase kinase 3 in squamous
differentiation induced by cigarette smoke in porcine
tracheobronchial epithelial cells. Food Chem Toxicol. 44:1590–1596.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
114
|
Zheng H, Saito H, Masuda S, Yang X and
Takano Y: Phosphorylated GSK3beta-ser9 and EGFR are good prognostic
factors for lung carcinomas. Anticancer Res. 27:3561–3569.
2007.PubMed/NCBI
|
|
115
|
Oren M: Decision making by p53: Life,
death and cancer. Cell Death Differ. 10:431–442. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
116
|
Gao S, Brown J, Wang H and Feng X: The
role of glycogen synthase kinase 3-β in immunity and cell cycle:
Implications in esophageal cancer. Arch Immunol Ther Exp (Warsz).
62:131–144. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
117
|
Maneckjee R, Biswas R and Vonderhaar BK:
Binding of opioids to human MCF-7 breast cancer cells and their
effects on growth. Cancer Res. 50:2234–2238. 1990.PubMed/NCBI
|
|
118
|
Hatzoglou A, Bakogeorgou E and Castanas E:
The antiproliferative effect of opioid receptor agonists on the
T47D human breast cancer cell line, is partially mediated through
opioid receptors. Eur J Pharmacol. 296:199–207. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
119
|
Montagna G, Gupta HV, Hannum M, Tan KS,
Lee J, Scarpa JR, Plitas G, Irie T, McCormick PJ, Fischer GW, et
al: Intraoperative opioids are associated with improved
recurrence-free survival in triple-negative breast cancer. Br J
Anaesth. 126:367–376. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
120
|
Abnet CC, Arnold M and Wei WQ:
Epidemiology of esophageal squamous cell carcinoma.
Gastroenterology. 154:360–373. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
121
|
Zylla D, Gourley BL, Vang D, Jackson S,
Boatman S, Lindgren B, Kuskowski MA, Le C, Gupta K and Gupta P:
Opioid requirement, opioid receptor expression, and clinical
outcomes in patients with advanced prostate cancer. Cancer.
119:4103–4110. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
122
|
Harper P, Hald O, Lwaleed BA, Kyyaly A,
Johnston D, Cooper AJ and Birch B: The impact of morphine treatment
on bladder cancer cell proliferation and apoptosis: In vitro
studies. Exp Oncol. 40:190–193. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
123
|
Moon TD: The effect of opiates upon
prostatic carcinoma cell growth. Biochem Biophys Res Commun.
153:722–727. 1988. View Article : Google Scholar : PubMed/NCBI
|
|
124
|
Kampa M, Bakogeorgou E, Hatzoglou A,
Damianaki A, Martin PM and Castanas E: Opioid alkaloids and
casomorphin peptides decrease the proliferation of prostatic cancer
cell lines (LNCaP, PC3 and DU145) through a partial interaction
with opioid receptors. Eur J Pharmacol. 335:255–265. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
125
|
Kampa M, Loukas S, Tsapis A and Castanas
E: Receptorphin: A conserved peptide derived from the sequence of
the opioid receptor, with opioid displacement activity and potent
antiproliferative actions in tumor cells. BMC Pharmacol. 1:92001.
View Article : Google Scholar : PubMed/NCBI
|
|
126
|
Yamashita H, Shuman L, Warrick JI, Raman
JD and Degraff DJ: Androgen represses opioid growth factor receptor
(OGFR) in human prostate cancer LNCaP cells and OGFR expression in
human prostate cancer tissue. Am J Clin Exp Urol. 6:164–171.
2018.PubMed/NCBI
|
|
127
|
Lec PM, Lenis AT, Golla V, Brisbane W,
Shuch, Garraway IP, Reiter RE and Chamie K: The role of opioids and
their receptors in urological malignancy: A review. J Urol.
204:1150–1159. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
128
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
129
|
Bohn LM, Belcheva MM and Coscia CJ:
Evidence for kappa- and mu-opioid receptor expression in C6 glioma
cells. J Neurochem. 70:1819–1825. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
130
|
Remmers AE, Clark MJ, Mansour A, Akil H,
Woods JH and Medzihradsky F: Opioid efficacy in a C6 glioma cell
line stably expressing the human kappa opioid receptor. J Pharmacol
Exp Ther. 288:827–833. 1999.PubMed/NCBI
|
|
131
|
Giakoumettis D, Kritis A and Foroglou N:
C6 cell line: The gold standard in glioma research. Hippokratia.
22:105–112. 2018.PubMed/NCBI
|
|
132
|
Bohn LM, Belcheva MM and Coscia CJ:
Mitogenic signaling via endogenous kappa-opioid receptors in C6
glioma cells: Evidence for the involvement of protein kinase C and
the mitogen-activated protein kinase signaling cascade. J
Neurochem. 74:564–573. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
133
|
Bohn LM, Belcheva MM and Coscia CJ:
Mu-opioid agonist inhibition of kappa-opioid receptor-stimulated
extracellular signal-regulated kinase phosphorylation is
dynamin-dependent in C6 glioma cells. J Neurochem. 74:574–581.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
134
|
Kampa M, Margioris AN, Hatzoglou A,
Dermitzaki I, Denizot A, Henry JF, Oliver C, Gravanis A and
Castanas E: Kappa1-opioid binding sites are the dominant opioid
binding sites in surgical specimens of human pheochromocytomas and
in a human pheochromocytoma (KAT45) cell line. Eur J Pharmacol.
364:255–262. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
135
|
Venihaki M, Gravanis A and Margioris AN:
Kappa opioids exert a strong antiproliferative effect on PC12 rat
pheochromocytoma cells. Peptides. 17:413–419. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
136
|
Takekoshi K, Ishii K, Kawakami Y, Isobe K
and Nakai T: kappa-Opioid inhibits catecholamine biosynthesis in
PC12 rat pheochromocytoma cell. FEBS Lett. 477:273–277. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
137
|
Chatzaki E, Margioris AN, Makrigiannakis
A, Castanas E, Georgoulias V and Gravanis A: Kappa opioids and
TGFbeta1 interact in human endometrial cells. Mol Hum Reprod.
6:602–609. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
138
|
Li WW, Zhao WJ, Yang Y and Yang YM:
Effects of TGF-β1 on the expression of endometrial stromal
cell-related protein and mRNA. Eur Rev Med Pharmacol Sci.
24:11475–11480. 2020.PubMed/NCBI
|
|
139
|
Chatzaki E, Kouimtzoglou E, Margioris AN
and Gravanis A: Transforming growth factor beta1 exerts an
autocrine regulatory effect on human endometrial stromal cell
apoptosis, involving the FasL and Bcl-2 apoptotic pathways. Mol Hum
Reprod. 9:91–95. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
140
|
Chamouard P, Klein A, Martin E, Adloff M
and Angel F: Regulatory role of enteric kappa opioid receptors in
human colonic motility. Life Sci. 53:1149–1156. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
141
|
Sherman SK, Maxwell JE, Carr JC, Wang D,
Bellizzi AM, O'Dorisio MS, O'Dorisio TM and Howe JR: Gene
expression accurately distinguishes liver metastases of small bowel
and pancreas neuroendocrine tumors. Clin Exp Metastasis.
31:935–944. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
142
|
Li T, Kang G, Wang T and Huang H: Tumor
angiogenesis and anti-angiogenic gene therapy for cancer. Oncol
Lett. 16:687–702. 2018.PubMed/NCBI
|
|
143
|
Mody K, Baldeo C and Bekaii-Saab T:
Antiangiogenic therapy in colorectal cancer. Cancer J. 24:165–170.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
144
|
Al-Husein B, Abdalla M, Trepte M, Deremer
DL and Somanath PR: Antiangiogenic therapy for cancer: An update.
Pharmacotherapy. 32:1095–1111. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
145
|
Carmeliet P: VEGF as a key mediator of
angiogenesis in cancer. Oncology. 69 (Suppl 3):S4–S10. 2005.
View Article : Google Scholar
|
|
146
|
Olejarz W, Kubiak-Tomaszewska G,
Chrzanowska A and Lorenc T: Exosomes in angiogenesis and
anti-angiogenic therapy in cancers. Int J Mol Sci. 21:58402020.
View Article : Google Scholar : PubMed/NCBI
|
|
147
|
Pujade-Lauraine E, Hilpert F, Weber B,
Reuss A, Poveda A, Kristensen G, Sorio R, Vergote I, Witteveen P,
Bamias A, et al: Bevacizumab combined with chemotherapy for
platinum-resistant recurrent ovarian cancer: The AURELIA open-label
randomized phase III trial. J Clin Oncol. 32:1302–1308. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
148
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
149
|
Rini BI, Bellmunt J, Clancy J, Wang K,
Niethammer AG, Hariharan S and Escudier B: Randomized phase III
trial of temsirolimus and bevacizumab versus interferon alfa and
bevacizumab in metastatic renal cell carcinoma: INTORACT trial. J
Clin Oncol. 32:752–759. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
150
|
Bear HD, Tang G, Rastogi P, Geyer CE Jr,
Liu Q, Robidoux A, Baez-Diaz L, Brufsky AM, Mehta RS, Fehrenbacher
L, et al: Neoadjuvant plus adjuvant bevacizumab in early breast
cancer [NSABP B-40 (NRG Oncology)]: Secondary outcomes of a phase
3, randomised controlled trial. Lancet Oncol. 16:1037–1048. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
151
|
Yamamizu K, Furuta S, Hamada Y, Yamashita
A, Kuzumaki N and Narita M, Doi K, Katayama S, Nagase H, Yamashita
JK and Narita M: к Opioids inhibit tumor angiogenesis by
suppressing VEGF signaling. Sci Rep. 3:32132013. View Article : Google Scholar : PubMed/NCBI
|
|
152
|
Yamamizu K and Yamashita JK: Roles of
cyclic adenosine monophosphate signaling in endothelial cell
differentiation and arterial-venous specification during vascular
development. Circ J. 75:253–260. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
153
|
Singh N, Baby D, Rajguru JP, Patil PB,
Thakkannavar SS and Pujari VB: Inflammation and cancer. Ann Afr
Med. 18:121–126. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
154
|
Elinav E, Nowarski R, Thaiss CA, Hu B, Jin
C and Flavell RA: Inflammation-induced cancer: Crosstalk between
tumours, immune cells and microorganisms. Nat Rev Cancer.
13:759–771. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
155
|
Chuang TK, Killam KF Jr, Chuang LF, Kung
HF, Sheng WS, Chao CC, Yu L and Chuang RY: Mu opioid receptor gene
expression in immune cells. Biochem Biophys Res Commun.
216:922–930. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
156
|
Kao TK, Ou YC, Liao SL, Chen WY, Wang CC,
Chen SY, Chiang AN and Chen CJ: Opioids modulate post-ischemic
progression in a rat model of stroke. Neurochem Int. 52:1256–1265.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
157
|
Zhang P, Yang M, Chen C, Liu L, Wei X and
Zeng S: Toll-Like receptor 4 (TLR4)/opioid receptor pathway
crosstalk and impact on opioid analgesia, immune function, and
gastrointestinal motility. Front Immunol. 11:14552020. View Article : Google Scholar : PubMed/NCBI
|
|
158
|
Eisenstein TK: The role of opioid
receptors in immune system function. Front Immunol. 10:29042019.
View Article : Google Scholar : PubMed/NCBI
|
|
159
|
Finley MJ, Happel CM, Kaminsky DE and
Rogers TJ: Opioid and nociceptin receptors regulate cytokine and
cytokine receptor expression. Cell Immunol. 252:146–154. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
160
|
Multhoff G and Vaupel P: Hypoxia
compromises anti-cancer immune responses. Adv Exp Med Biol.
1232:131–143. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
161
|
Dehne N, Mora J, Namgaladze D, Weigert A
and Brüne B: Cancer cell and macrophage cross-talk in the tumor
microenvironment. Curr Opin Pharmacol. 35:12–19. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
162
|
Xi C, Liang X, Chen C, Babazada H, Li T
and Liu R: Hypoxia induces internalization of κ-opioid receptor.
Anesthesiology. 126:842–854. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
163
|
Babcock J, Herrera A, Coricor G, Karch C,
Liu AH, Rivera-Gines A and Ko JL: Mechanism governing human
kappa-opioid receptor expression under desferrioxamine-induced
hypoxic mimic condition in neuronal NMB cells. Int J Mol Sci.
18:2112017. View Article : Google Scholar : PubMed/NCBI
|
|
164
|
Brownstein MJ: A brief history of opiates,
opioid peptides, and opioid receptors. Proc Natl Acad Sci USA.
90:5391–5393. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
165
|
Meuser T, Pietruck C, Radbruch L, Stute P,
Lehmann KA and Grond S: Symptoms during cancer pain treatment
following WHO-guidelines: A longitudinal follow-up study of symptom
prevalence, severity and etiology. Pain. 93:247–257. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
166
|
Zylla D, Steele G and Gupta P: A
systematic review of the impact of pain on overall survival in
patients with cancer. Support Care Cancer. 25:1687–1698. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
167
|
Boland JW and Pockley AG: Influence of
opioids on immune function in patients with cancer pain: From bench
to bedside. Br J Pharmacol. 175:2726–2736. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
168
|
Juneja R: Opioids and cancer recurrence.
Curr Opin Support Palliat Care. 8:91–101. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
169
|
Amaram-Davila J, Davis M and Reddy A:
Opioids and cancer mortality. Curr Treat Options Oncol. 21:222020.
View Article : Google Scholar : PubMed/NCBI
|
|
170
|
Fujiwara Y, Yamamoto H and Monden M:
Molecular biology-based surgery for the future progress of cancer
treatment. Nihon Geka Gakkai Zasshi. 103:278–283. 2002.(In
Japanese). PubMed/NCBI
|
|
171
|
Hashizume M and Tsugawa K: Robotic surgery
and cancer: The present state, problems and future vision. Jpn J
Clin Oncol. 34:227–237. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
172
|
Baskar R, Lee KA, Yeo R and Yeoh KW:
Cancer and radiation therapy: Current advances and future
directions. Int J Med Sci. 9:193–199. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
173
|
Lee YT, Tan YJ and Oon CE: Molecular
targeted therapy: Treating cancer with specificity. Eur J
Pharmacol. 834:188–196. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
174
|
Cross D and Burmester JK: Gene therapy for
cancer treatment: Past, present and future. Clin Med Res.
4:218–227. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
175
|
Chen WK and Miao CH: The effect of
anesthetic technique on survival in human cancers: A meta-analysis
of retrospective and prospective studies. PLoS One. 8:e565402013.
View Article : Google Scholar : PubMed/NCBI
|
|
176
|
Gach K, Wyrębska A, Fichna J and Janecka
A: The role of morphine in regulation of cancer cell growth. Naunyn
Schmiedebergs Arch Pharmacol. 384:221–230. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
177
|
Forget P, Aguirre JA, Bencic I, Borgeat A,
Cama A, Condron C, Eintrei C, Eroles P, Gupta A, Hales TG, et al:
How anesthetic, analgesic and other non-surgical techniques during
cancer surgery might affect postoperative oncologic outcomes: A
summary of current state of evidence. Cancers (Basel). 11:5922019.
View Article : Google Scholar : PubMed/NCBI
|
|
178
|
Liu B, Liu Y, Li N, Zhang J and Zhang X:
Oxycodone regulates incision-induced activation of neurotrophic
factors and receptors in an acute post-surgery pain rat model. J
Pain Res. 11:2663–2674. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
179
|
Ji J, Lin W, Vrudhula A, Xi J, Yeliseev A,
Grothusen JR, Bu W and Liu R: Molecular interaction between
butorphanol and κ-opioid receptor. Anesth Analg. 131:935–942. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
180
|
Tian M, Jin L, Li R, Zhu S, Ji M and Li W:
Comparison of oxycodone and morphine on the proliferation,
apoptosis and expression of related molecules in the A549 human
lung adenocarcinoma cell line. Exp Ther Med. 12:559–566. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
181
|
Yu Y, Li D, Duan J, Xu H, Li L, Tan D and
Yan H: The pro- and anti-cancer effects of oxycodone are associated
with epithelial growth factor receptor level in cancer cells.
Biosci Rep. 40:BSR201935242020. View Article : Google Scholar : PubMed/NCBI
|
|
182
|
Gery S, Yin D, Xie D, Black KL and
Koeffler HP: TMEFF1 and brain tumors. Oncogene. 22:2723–2727. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
183
|
Nie X, Gao L, Zheng M, Wang C, Wang S, Li
X, Qi Y, Zhu L, Liu J and Lin B: Overexpression of TMEFF1 in
endometrial carcinoma and the mechanism underlying its promotion of
malignant behavior in cancer cells. J Cancer. 12:5772–5788. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
184
|
Nie X, Liu C, Guo Q, Zheng MJ, Gao LL, Li
X, Liu DW, Zhu LC, Liu JJ and Lin B: TMEFF1 overexpression and its
mechanism for tumor promotion in ovarian cancer. Cancer Manag Res.
11:839–855. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
185
|
Wang B, Li Y, Shen Y, Xu Y and Zhang C:
Butorphanol inhibits the malignant biological behaviors of ovarian
cancer cells via down-regulating the expression of TMEFF1. Onco
Targets Ther. 13:10973–10981. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
186
|
Ramirez MF, Gorur A and Cata JP: Opioids
and cancer prognosis: A summary of the clinical evidence. Neurosci
Lett. 746:1356612021. View Article : Google Scholar : PubMed/NCBI
|
|
187
|
Wang YH, Sun JF, Tao YM, Chi ZQ and Liu
JG: The role of kappa-opioid receptor activation in mediating
antinociception and addiction. Acta Pharmacol Sin. 31:1065–1070.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
188
|
Torre LA, Siegel RL, Ward EM and Jemal A:
Global cancer incidence and mortality rates and trends-an update.
Cancer Epidemiol Biomarkers Prev. 25:16–27. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
189
|
Ramirez MF, Gorur A and Cata JP: The role
of opioids in cancer progression. Int Anesthesiol Clin Spring.
58:57–63. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
190
|
Rodrigue D, Winkelmann J, Price M,
Kalandranis E, Klempner L and Kapoor-Hintzen N: Opioid misuse: An
organizational response while managing cancer-related pain. Clin J
Oncol Nurs. 24:170–176. 2020. View Article : Google Scholar : PubMed/NCBI
|
|
191
|
Schmidhammer H, Erli F, Guerrieri E and
Spetea M: Development of diphenethylamines as selective kappa
opioid receptor ligands and their pharmacological activities.
Molecules. 25:50922020. View Article : Google Scholar : PubMed/NCBI
|
